Unattributed Code Systems

• urn:ietf:bcp:47
• urn:oid:2.16.840.1.113883.6.238

Copyright Fragment

This fragment is available on downloads.html

Copyright and Registered Trademark Uses

• IG © 2021+ HL7 International / Public Health. Package hl7.fhir.us.central-cancer-registry-reporting#2.0.0-ballot based on FHIR 4.0.1. Generated 2025-09-02 Links: Table of Contents | QA Report | Version History | CC0 | Propose a change ( src )
• hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )
• Advances in medicine and changes in the healthcare delivery system now allow patients to obtain their care outside the acute care hospital setting. Data collection systems from ambulatory healthcare providers such as physician offices and radiation therapy centers are not as standardized or complete with respect to reporting of cancer occurrences and treatment. When reporting does occur, it may be through a manual process of identifying reportable cases and submitting paper copies of the medical record, or the central registry may send certified tumor registrars (CTRs) to ambulatory healthcare provider offices to abstract the information manually or electronically from the paper-based medical records. The Health Level 7 (HL7) Clinical Document Architecture (CDA®) Release 2 Implementation Guide (IG): Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, Release 1, DSTU Release 1.1 – US Realm is the first standard for ambulatory care to use when electronically transmitting cancer cases to the central cancer registry. The CDA IG is part of the Office of the National Coordinator (ONC) Meaningful Use and identifies the content and structure for reporting from physician electronic health records (EHRs) to central cancer registries (CCRs), but it does not use HL7 Fast Healthcare Interoperability Resources (FHIR®). These processes are very resource intensive, time-consuming, prone to errors in transcription, and inherently less secure. This leads to under-reporting of certain types of cancers, especially those now diagnosed and treated primarily outside of hospitals, such as in dermatology, urology, and hematology, as well as under-reporting of treatment information across most types of cancer. ( src )
• Central Cancer Registry Reporting Content IG, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-central-cancer-registry-reporting-ig/ and changes regularly. See the Directory of published versions ( src )
• Health Level 7 (HL7) Clinical Document Architecture (CDA®) Release 2 Implementation Guide (IG): Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, Release 1, DSTU Release 1.1 – US Realm ( src )
• The goal of the Central Cancer Registry Reporting Content IG is to automate the capture of cancer cases and cancer treatment information and provide incidence data faster for research and public health. The Central Cancer Registry Reporting Content IG will leverage existing FHIR® infrastructure to transmit cancer case information primarily from ambulatory care practices to central cancer registries. Additionally, this use case aims to identify data standards that allow for the collection and transmission of these data electronically from EHRs automatically rather than relying on labor-intensive manual processes and duplications of effort. ( src )
• This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: Bundle/ccrr-content-bundle-example, Bundle/reporting-bundle-example... Show 5 more , CcrrComposition, Composition/ccrr-composition-example, Observation/cancer-stage-group-example, Observation/tnm-clinical-primary-tumor-category-cT3 and Observation/tnm-clinical-regional-nodes-category-cN3 ( src )
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * AllergyIntolerance Clinical Status Codes: AllergyIntolerance/example * AllergyIntolerance Verification Status: AllergyIntolerance/example * Condition Category Codes: Condition/primary-cancer-condition-breast * Condition Clinical Status Codes: Condition/primary-cancer-condition-breast * ConditionVerificationStatus: Condition/primary-cancer-condition-breast * Endpoint Connection Type: HealthCareSenderAndReceiver and PHAReceiver * Observation Category Codes: Observation/cancer-stage-group-example, Observation/tnm-clinical-distant-metastases-category-cM0, Observation/tnm-clinical-primary-tumor-category-cT3 and Observation/tnm-clinical-regional-nodes-category-cN3 * PlanDefinitionType: Bundle/central-cancer-registry-reporting-specification-bundle-example, CentralCancerRegistryReportingExample and CentralCancerRegistryReportingPlanDefinition * identifierType: Patient/example and Practitioner/1 * ActCode: Encounter/encounter-cancer-example * NullFlavor: Procedure/radiotherapy-example * ParticipationType: CentralCancerRegistryReportingEncounter and Encounter/encounter-cancer-example ( src )
• This set of FHIR profiles was produced and developed through the efforts of a project of the National Institute of Occupational Safety and Health (NIOSH), the U.S. federal agency responsible for conducting research and making recommendations for the prevention of work-related injury and illness. NIOSH is a part of the U.S. Centers for Disease Control and Prevention (CDC). NIOSH consulted stakeholders in clinical care, public health, health IT, health informatics and U.S. government agencies to develop ODH. The HL7® Public Health and Emergency Response Work Group sponsored development of this set of FHIR profiles. Co-sponsoring HL7® Work Groups were Orders and Observations (OO), Patient Administration (PA), and Clinical Quality Initiative (CQI). The following individuals provided subject matter expertise for this set of FHIR profiles: Genevieve Barkocy Luensman, NIOSH; Eileen Storey, Professional Services Partners, formerly NIOSH; Margaret S. Filios, NIOSH; Christina Socias-Morales, NIOSH; Lauren Brewer, NIOSH; Barbara Wallace, Professional Services Partners. ( src )
• This value set includes content from SNOMED CT, which is copyright © 2002+ International Health Terminology Standards Development Organisation (IHTSDO), and distributed by agreement between IHTSDO and HL7. Implementer use of SNOMED CT is not covered by this agreement. 2. ICD-9 and ICD-10 are copyrighted by the World Health Organization (WHO) which owns and publishes the classification. See https://www.who.int/classifications/icd/en. WHO has authorized the development of an adaptation of ICD-9 and ICD-10 to ICD-9-CM to ICD-10-CM for use in the United States for U.S. government purposes. ( src )

External References